Publicacións en colaboración con investigadores/as de Complexo Hospitalario Universitario de Santiago (28)

2024

  1. Efficacy of Beclomethasone Dipropionate in Lowering Fecal Calprotectin Levels in Patients with Ulcerative Colitis in Clinical Remission and at Risk of Relapse: The Becalcu Randomized, Controlled Trial

    Digestive Diseases

2023

  1. Managing ulcerative colitis after surgery

    Frontiers in Medicine

2022

  1. Correction: Chaparro et al. Incidence, Clinical Characteristics and Management of Inflammatory Bowel Disease in Spain: Large-Scale Epidemiological Study (J. Clin. Med., (2021), 10, (2885), 10.3390/jcm10132885)

    Journal of Clinical Medicine

  2. Management and Long-term Outcomes of Crohn's Disease Complicated with Enterocutaneous Fistula: ECUFIT Study from GETECCU

    Journal of Crohn's & colitis, Vol. 16, Núm. 7, pp. 1049-1058

  3. Radon exposure and inflammatory bowel disease in a radon prone area

    Revista espanola de enfermedades digestivas : organo oficial de la Sociedad Espanola de Patologia Digestiva, Vol. 114, Núm. 7, pp. 405-409

  4. Recommendations of the Spanish Group on Crohn's Disease and Ulcerative Colitis on the importance, screening and vaccination in inflammatory bowel disease patients

    Gastroenterologia y Hepatologia, Vol. 45, Núm. 10, pp. 805-818

  5. SARS-CoV-2 vaccine acceptance among gastroenterologists and inflammatory bowel disease patients: VACUNEII project

    Gastroenterologia y Hepatologia, Vol. 45, Núm. 10, pp. 737-741

  6. The Impact of Vedolizumab and Ustekinumab on Articular Extra-Intestinal Manifestations in Inflammatory Bowel Disease Patients: A Real-Life Multicentre Cohort Study

    Journal of Crohn's & colitis, Vol. 16, Núm. 11, pp. 1676-1686

  7. Treatment patterns and intensification within 5 year of follow-up of the first-line anti-TNFα used for the treatment of IBD: Results from the VERNE study

    Digestive and Liver Disease, Vol. 54, Núm. 1, pp. 76-83

  8. Usefulness of peripheral blood monocyte count to predict relapse in patients with inflammatory bowel disease: a prospective longitudinal cohort study

    Revista espanola de enfermedades digestivas : organo oficial de la Sociedad Espanola de Patologia Digestiva, Vol. 114, Núm. 1, pp. 10-15

  9. Validation of screening criteria for spondyloarthritis in patients with inflammatory bowel disease in routine clinical practice

    Digestive and Liver Disease, Vol. 54, Núm. 6, pp. 755-762

2021

  1. Incidence, clinical characteristics and management of inflammatory bowel disease in spain: Large-scale epidemiological study

    Journal of Clinical Medicine, Vol. 10, Núm. 13

  2. Liver X Receptor Exerts Anti-Inflammatory Effects in Colonic Epithelial Cells via ABCA1 and Its Expression Is Decreased in Human and Experimental Inflammatory Bowel Disease

    Inflammatory Bowel Diseases, Vol. 27, Núm. 10, pp. 1661-1673

  3. Preferences and satisfaction of IBD patients after switching from adalimumab 40 mg weekly to 80 mg every other week given as a single injection: the ADASCAL study

    Therapeutic Advances in Gastroenterology, Vol. 14

  4. Role of quality of life as endpoint for inflammatory bowel disease treatment

    International Journal of Environmental Research and Public Health, Vol. 18, Núm. 13

2020

  1. Early treatment with anti-tumor necrosis factor agents improves long-term effectiveness in symptomatic stricturing Crohn’s disease

    United European Gastroenterology Journal, Vol. 8, Núm. 9, pp. 1056-1066

  2. Usefulness of monitoring antitumor necrosis factor serum levels during the induction phase in patients with Crohn's disease

    European Journal of Gastroenterology and Hepatology, Vol. 32, Núm. 5, pp. 588-596

2019

  1. Anti-tumour necrosis factor discontinuation in inflammatory bowel disease patients in remission: study protocol of a prospective, multicentre, randomized clinical trial

    Therapeutic Advances in Gastroenterology, Vol. 12

  2. Correlation Between Anti-TNF Serum Levels and Endoscopic Inflammation in Inflammatory Bowel Disease Patients

    Digestive Diseases and Sciences, Vol. 64, Núm. 3, pp. 846-854

  3. Functional rare variants influence the clinical response to anti-TNF therapy in Crohn’s disease

    Therapeutic Advances in Gastroenterology, Vol. 12